Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5921125 | Cardiovascular Revascularization Medicine | 2015 | 4 Pages |
Abstract
Available data on the use of the ABSORB BVS in real-world patients is limited. We retrospectively evaluated all patients treated with ABSORB BVS between July 2012 and July 2014. A total of 108 patients (126 lesions) were identified. Clinical presentation was equally divided between stable angina and acute coronary syndrome (51.8% vs. 48.2%, p = 0.59). Predilatation (92.9%) and postdilatation (82.5%) were frequently performed. Estimated MACE rates at 6-month and 1-year were 2.5% and 4.5% respectively, with a 1-year TLF rate of 1.9%. These results suggest that the use of ABSORB BVS use in the real-world is associated with good mid-term clinical outcomes when guided by intravascular imaging.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Medicine
Authors
Charis Costopoulos, Matthew C. Crowson, Adam J. Brown, Denise M. Braganza, Martin R. Bennett, Stephen P. Hoole, Nick E.J. West,